Perhexiline Demonstrates FYN-mediated Antitumor Activity in Glioblastoma.

Document Type

Article

Publication Date

7-1-2020

Publication Title

Molecular cancer therapeutics

Abstract

Glioblastoma is the most common primary malignant brain tumor in adults. Despite aggressive treatment, outcomes remain poor with few long-term survivors. Therefore, considerable effort is being made to identify novel therapies for this malignancy. Targeting tumor metabolism represents a promising therapeutic strategy and activation of fatty acid oxidation (FAO) has been identified as a central metabolic node contributing toward gliomagenesis. Perhexiline is a compound with a long clinical track record in angina treatment and commonly described as an FAO inhibitor. We therefore sought to determine whether this compound might be repurposed to serve as a novel therapy in glioblastoma. Perhexiline demonstrated potent

Volume

19

Issue

7

First Page

1415

Last Page

1422

DOI

10.1158/1535-7163

ISSN

1538-8514

PubMed ID

32430486

Link to Full Text

Share

COinS